Published: 5 January 2016
Author(s): Thomas C. Sauter, Anna-Lea Amylidi, Meret E. Ricklin, Beat Lehmann, Aristomenis K. Exadaktylos
Issue: January 2016
Section: Letter to the Editor

Since 2009, an increasing number of patients presenting to emergency departments (ED) are on anticoagulant medication with the newer direct oral anticoagulants (NOAC), such as rivaroxaban (Xarelto), apixaban (Eliquis), and dabigatran (Pradaxa). Important advantages of these agents are easier therapy management, faster onset of therapeutic effect, and an increasing range of approved indications in comparison to the classic Vitamin-K antagonists (VKA) such as warfarin and phenprocoumon (Marcoumar).


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.